Leuprolide Monotherapy for Choroidal Metastasis From Prostate Adenocarcinoma | Intraocular Tumors | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.108.182. Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
Research Letter
Sep 2012

Leuprolide Monotherapy for Choroidal Metastasis From Prostate Adenocarcinoma

Author Affiliations

Author Affiliations: Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston (Drs Ameri and Gombos), and Department of Genitourinary Medical Oncology, Division of Cancer Medicine (Dr Araujo) and Section of Ophthalmology, Department of Head and Neck Surgery, Division of Surgery (Dr Gombos), The University of Texas MD Anderson Cancer Center, Houston.

Arch Ophthalmol. 2012;130(9):1225-1226. doi:10.1001/archophthalmol.2012.458

Prostate cancer is the most common malignant neoplasm in men in developed countries and the second most common worldwide.1 Androgen deprivation therapy is often used for recurrent or metastatic disease. Gonadotropin-releasing hormone agonists such as leuprolide acetate are the most frequently used medications for this purpose.2

Prostate cancer rarely metastasizes to the choroid. A large retrospective study found prostate cancer to be the primary site in only 6% of patients with uveal metastasis.3

In addition to hormonal therapy, patients with choroidal metastasis have been traditionally treated with external beam radiation or brachytherapy.4 We report a case of choroidal metastasis from prostate cancer successfully treated with leuprolide alone.

×